Synchronous multiple primary malignant neoplasms: a case report of malignant peritoneal mesothelioma and neuroendocrine rectal tumor
We report a rare case of synchronous malignant peritoneal mesothelioma of the biphasic histological type and neuroendocrine tumor (NET) of the rectum without history of asbestos exposure.
During 2 years since manifestation of the disease the patient underwent 3 cytoreductive surgeries (CRS): removal of the tumor of the sigmoid mesentery, resection of the rectosigmoid junction completeness of cytoreduction (CC) 0 (2017), omentectomy and partial parietal peritonectomy CC-0 (2017), atypical resection of S2, S4, S5 liver, the removal of the abdominal tumor with left-sided en-block hemicolectomy, partial parietal peritonectomy, argon-plasma coagulation of tumor foci on the mesentery of the small intestine CC-2 (2018) and Transanal Minimally Invasive Surgery-removal of neuroendocrine rectal tumor (2017). The patient underwent hyperthermic intraperitoneal chemotherapy (HIPEC) twice (during 2nd and 3rd CRS). Different regimens of HIPEC were performed: cisplatin + doxorubicin (2017) and metamycin C (2018). The patient received 4 courses of adjuvant chemotherapy with cisplatin plus pemetrexed in 2017 and 3 courses of the chemotherapy with gemcitabine and carboplatin plus bevacizumab in 2018.
The patient survived 21 months after the detection of malignant peritoneal mesothelioma in 2017 and died 4 months after the last cytoreductive surgery from the progression of the disease.
Histological subtype of MPMP remains important factor in the prognosis of the disease even on the early stages though patient had received the most aggressive variant of special treatment. Minimally invasive treatment tactics of NET demonstrated clinical effectiveness.
Zhai, C., Cai, Y., Lou, F., Liu, Z., Xie, J., Zhou, X. et. al. (2018). Multiple Primary Malignant Tumors - A Clinical Analysis of 15,321 Patients with Malignancies at a Single Center in China. Journal of Cancer, 9 (16), 2795–2801. doi: http://doi.org/10.7150/jca.25482
Ozbudak, I. H., Ozbudak, O., Arslan, G., Erdogan, A., Ozbilim, G. (2013). Metachronous malignant mesothelioma and pulmonary adenocarcinoma. Turkish Journal of Pathology, 29 (1), 83–86. doi: http://doi.org/10.5146/tjpath.2013.01156
Kusamura, S., Kepenekian, V., Villeneuve, L., Lurvink, R. J., Govaerts, K., De Hingh, I. H. J. T. et. al. (2021). Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. European Journal of Surgical Oncology, 47 (1), 36–59. doi: http://doi.org/10.1016/j.ejso.2020.02.011
Boussios, S., Moschetta, M., Karathanasi, A., Tsiouris, A. K., Kanellos, F. S., Tatsi, K. et. al. (2018). Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. Annals of gastroenterology, 31 (6), 659–669. doi: http://doi.org/10.20524/aog.2018.0305
Rakici, H., Akdogan, R. A., Yurdakul, C., Canturk, N. (2015). A case of rectal neuroendocrine tumor presenting as polyp. International Journal of Surgery Case Reports, 8, 59–61. doi: http://doi.org/10.1016/j.ijscr.2015.01.031
Scherübl, H. (2011). Management of early gastrointestinal neuroendocrine neoplasms. World Journal of Gastrointestinal Endoscopy, 3 (7), 133–139. doi: http://doi.org/10.4253/wjge.v3.i7.133
Chablaney, S., Zator, Z. A., Kumta, N. A. (2017). Diagnosis and Management of Rectal Neuroendocrine Tumors. Clinical Endoscopy, 50 (6), 530–536. doi: http://doi.org/10.5946/ce.2017.134
Kim, J., Bhagwandin, S., Labow, D. M. (2017). Malignant peritoneal mesothelioma: a review. Annals of Translational Medicine, 5 (11), 236–236. doi: http://doi.org/10.21037/atm.2017.03.96
Marques de Sousa, S., Pereira, F., Duarte, M., Marques, M., Vázquez, D., Marques, C. (2019). Malignant Peritoneal Mesothelioma as a Rare Cause of Dyspeptic Complaints and Ascites: A Diagnostic Challenge. GE - Portuguese Journal of Gastroenterology, 27 (3), 197–202. doi: http://doi.org/10.1159/000503075
Amin, W., Linkov, F., Landsittel, D. P., Silverstein, J. C., Bshara, W., Gaudioso, C. et. al. (2019). Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. F1000Research, 7, 1184. doi: http://doi.org/10.12688/f1000research.15512.3
Enomoto, L. M., Shen, P., Levine, E. A., Votanopoulos, K. I. (2019). Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations. Cancer Management and Research, 11, 4231–4241. doi: http://doi.org/10.2147/cmar.s170300
Broeckx, G., Pauwels, P. (2018). Malignant peritoneal mesothelioma: a review. Translational Lung Cancer Research, 7 (5), 537–542. doi: http://doi.org/10.21037/tlcr.2018.10.04
Copyright (c) 2021 Oleksandr Bondar, Sergiі Chetverikov, Viacheslav Maksymovskyi, Dmytro Atanasov, Mykhailo Chetverikov, Valeriia Chetverikova-Ovchynnyk
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.